Archive

Tag: Community Acquired Pneumonia

The SAFER Trial: Pediatric CAP – Amoxicillin 5 days vs 10 days

Background: The evidence supporting the use of a 10-day course of high-dose amoxicillin to treat community-acquired pneumonia (CAP) in pediatric patients is weak. In addition, medicine is trending towards shorter courses of antibiotics when clinically appropriate. REBEL EM covered a similar …

Read More
Infectious DiseaseThoracic and Respiratory

The Pneumonia Short Treatment Trial: Antibiotic Treatment for 3 days vs 8 days

Background: In 2019 the World Health Organization listed “Antimicrobial Resistance” as a top 10 threat to global health. This was echoed in a 2021 document. [WHO 2019, WHO 2021] The classic medical teaching regarding antimicrobial therapy pushed for longer treatment …

Read More
Infectious DiseaseThoracic and Respiratory

LEAP 2: Lefamulin vs Moxifloxacin for CAP

Background: Recently there have been some observed trends in decreasing susceptibility among Strep pneumoniae isolates to antimicrobials used to treat community acquired pneumonia (CAP) (Resistance to oral penicillin and macrolides for Strep pneumoniae & macrolides and fluoroquinolones for Staph aureus).  …

Read More
Infectious Disease

REBEL Core Cast 3.0 – Asthma, COPD + PNA

Take Home Points Single dose oral dexamethasone is an excellent choice for asthma exacerbations. It takes away the compliance issue for patients who have trouble getting medications or filling medications once they leave the ED. Antibiotics aren’t always indicated in …

Read More
Thoracic and Respiratory

Any Benefit to Adjunct Prednisone Therapy in Community Acquired Pneumonia?

Background: Respiratory tract infections and pneumonia are the 3rd leading cause of death worldwide.  Although morbidity and mortality has improved slightly with the advent of antibiotics, there is still a significant long-term morbidity and mortality associated with this disorder.  It …

Read More
Infectious Disease

Sponsored

0